Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death
S Bhattacharya,Alistair M. Chalk,Alvin J. M. Ng,Thomas J. Martin,Andrew C.W. Zannettino,Louise E. Purton,Jun Lu,Emma Baker,Carl R. Walkley +8 more
Reads0
Chats0
TLDR
Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS.Abstract:
Osteosarcoma (OS) is the most common cancer of bone and the 5th leading cause of cancer-related death in young adults. Currently, 5-year survival rates have plateaued at ~70% for patients with localized disease. Those with disseminated disease have an ~20% 5-year survival. An improved understanding of the molecular genetics of OS may yield new approaches to improve outcomes for OS patients. To this end, we applied murine models that replicate human OS to identify and understand dysregulated microRNAs (miRNAs) in OS. miRNA expression patterns were profiled in murine primary osteoblasts, osteoblast cultures and primary OS cell cultures (from primary and paired metastatic locations) isolated from two genetically engineered murine models of OS. The differentially expressed miRNA were further assessed by a cross-species comparison with human osteoblasts and OS cultures. We identified miR-155-5p and miR-148a-3p as deregulated in OS. miR-155-5p suppression or miR-148a-3p overexpression potently reduced proliferation and induced apoptosis in OS cells, yet strikingly, did not impact normal osteoblasts. To define how these miRNAs regulated OS cell fate, we used an integrated computational approach to identify putative candidate targets and then correlated these with the cell biological impact. Although we could not resolve the mechanism through which miR-148a-3p impacts OS, we identified that miR-155-5p overexpression suppressed its target Ripk1 (receptor (TNFRSF)-interacting serine-threonine kinase 1) expression, and miR-155-5p inhibition elevated Ripk1 levels. Ripk1 is directly involved in apoptosis/necroptosis. In OS cells, small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS. Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS.read more
Citations
More filters
Journal ArticleDOI
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
TL;DR: This review summarizes the current findings of miR-155 in hematopoietic lineage differentiation, the immune response, inflammation, and cancer therapy resistance, and discusses the potential of mi R-155-based therapeutic approaches for the treatment of cancer.
Journal ArticleDOI
Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma
Jinyan Wang,Yan Yang,Yajun Ma,Fen Wang,Aili Xue,Jing Zhu,Hui Yang,Qi Chen,Meili Chen,Lingling Ye,Hao Wu,Quan’an Zhang +11 more
TL;DR: The role of lncRNA-miRNA-mRNA axis in the development of OS is highlighted to provide novel approaches for cancer diagnosis and treatment.
Journal ArticleDOI
MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
TL;DR: It is found that miR‐155‐5p promoted proliferation, invasion and migration, but inhibited apoptosis in HCC by directly targeting the 3′‐UTR of PTEN through in vitro experiments, and in vivo as well.
Journal ArticleDOI
Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of rb, mimics the human disease
Carl R. Walkley,Rameez A. Qudsi,Vijay G. Sankaran,Monica Gostissa,Stanford I. Roth,Stephen J. Rodda,Erin Snay,Patricia Dunning,Frederic H. Fahey,Frederick W. Alt,Andrew P. McMahon,Stuart H. Orkin,Stuart H. Orkin +12 more
Journal ArticleDOI
miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses
TL;DR: The findings demonstrate the role of miR-19b-3p-SMAD4 axis in colon cancer progression, which may become a potential therapeutic target against chemotherapy resistance and confirmed that miR -19b -3p mediates resistance to oxaliplatin-based chemotherapy via SMAD4.
References
More filters
Journal ArticleDOI
MicroRNAs: Genomics, Biogenesis, Mechanism, and Function
TL;DR: Although they escaped notice until relatively recently, miRNAs comprise one of the more abundant classes of gene regulatory molecules in multicellular organisms and likely influence the output of many protein-coding genes.
Journal ArticleDOI
Treatment of HCV Infection by Targeting MicroRNA
Harry L.A. Janssen,Hendrik W. Reesink,Eric Lawitz,Stefan Zeuzem,Maribel Rodriguez-Torres,Keyur Patel,Adriaan J. van der Meer,Amy K. Patick,Alice Chen,Yi Zhou,Robert Persson,Barney D King,Sakari Kauppinen,Arthur A. Levin,Michael R. Hodges +14 more
TL;DR: The use of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance.
Journal ArticleDOI
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.
Nils Holler,Rossana Zaru,Olivier Micheau,Margot Thome,Antoine Attinger,Salvatore Valitutti,Jean-Luc Bodmer,Pascal Schneider,Brian Seed,Jürg Tschopp +9 more
TL;DR: F Fas kills activated primary T cells efficiently in the absence of active caspases, which results in necrotic morphological changes and late mitochondrial damage but no cytochrome c release.
Journal ArticleDOI
Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program
TL;DR: Osteosarcoma, which is the most common primary bone tumor, occurs most frequently in adolescents, but there is a second incidence peak among individuals aged >60 years, and direct comparisons among patients of all ages and ethnicities are not available.
Journal ArticleDOI
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Stefan S. Bielack,Beate Kempf-Bielack,Günter Delling,G. Ulrich Exner,Silke Flege,Knut Helmke,Rainer Kotz,Mechthild Salzer-Kuntschik,M. Werner,Winfried Winkelmann,Andreas Zoubek,Heribert Jürgens,Kurt Winkler +12 more
TL;DR: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.